ARHGEF39

Summary

ARHGEF39 (Rho guanine nucleotide exchange factor 39, HGNC:25909) is a protein-coding gene on chromosome 9p13.3, encoding Rho guanine nucleotide exchange factor 39 (Q8N4T4). Promotes cell proliferation.

Predicted to enable guanyl-nucleotide exchange factor activity. Involved in positive regulation of cell migration. Located in plasma membrane.

Source: NCBI Gene 84904 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 116 total — 1 pathogenic
• MANE Select transcript: NM_032818

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25909
Approved symbol	ARHGEF39
Name	Rho guanine nucleotide exchange factor 39
Location	9p13.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ14642
Ensembl gene	ENSG00000137135
Ensembl biotype	protein_coding
OMIM	621172
Entrez	84904

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 4 protein_coding, 3 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000378387, ENST00000468876, ENST00000475323, ENST00000488918, ENST00000490638, ENST00000490970, ENST00000935482, ENST00000935483, ENST00000935484

RefSeq mRNA: 1 — MANE Select: NM_032818 NM_032818

CCDS: CCDS6584

Canonical transcript exons

ENST00000378387 — 9 exons

Exon	Start	End
ENSE00000928216	35664756	35664850
ENSE00001252962	35662946	35663074
ENSE00001903032	35665032	35665195
ENSE00003502920	35662512	35662741
ENSE00003512786	35663322	35663392
ENSE00003524401	35664372	35664492
ENSE00003535301	35664008	35664126
ENSE00003576503	35662179	35662267
ENSE00003625725	35659343	35662002

Expression profiles

Bgee: expression breadth ubiquitous, 162 present calls, max score 86.36.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.9922 / max 100.7118, expressed in 1045 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
100599	5.9922	1045

Top tissues by expression

254 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.36	gold quality
tibial artery	UBERON:0007610	85.13	gold quality
popliteal artery	UBERON:0002250	85.11	gold quality
ventricular zone	UBERON:0003053	84.77	gold quality
aorta	UBERON:0000947	82.25	gold quality
mucosa of transverse colon	UBERON:0004991	82.00	gold quality
ascending aorta	UBERON:0001496	79.32	gold quality
thoracic aorta	UBERON:0001515	79.01	gold quality
body of stomach	UBERON:0001161	78.95	gold quality
rectum	UBERON:0001052	78.37	gold quality
mucosa of stomach	UBERON:0001199	77.87	gold quality
lower esophagus muscularis layer	UBERON:0035833	77.70	gold quality
lower esophagus	UBERON:0013473	77.66	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.62	gold quality
muscle layer of sigmoid colon	UBERON:0035805	77.41	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	77.23	gold quality
left coronary artery	UBERON:0001626	77.15	gold quality
transverse colon	UBERON:0001157	77.04	gold quality
descending thoracic aorta	UBERON:0002345	76.98	gold quality
right coronary artery	UBERON:0001625	76.22	gold quality
stomach	UBERON:0000945	75.62	gold quality
lower esophagus mucosa	UBERON:0035834	75.59	gold quality
coronary artery	UBERON:0001621	75.08	gold quality
ganglionic eminence	UBERON:0004023	74.66	gold quality
granulocyte	CL:0000094	74.64	gold quality
small intestine Peyer’s patch	UBERON:0003454	73.57	gold quality
esophagus	UBERON:0001043	73.54	gold quality
bone marrow cell	CL:0002092	73.39	gold quality
colon	UBERON:0001155	73.39	gold quality
large intestine	UBERON:0000059	72.38	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.36

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

118 targeting ARHGEF39, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-6793-5P	99.97	65.95	758
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-4648	99.91	67.00	710
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-4302	99.89	67.94	1187
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-202-3P	99.84	71.41	1290
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-8080	99.82	67.52	1342

Literature-anchored findings (GeneRIF, showing 6)

• C9orf100 plays a potential oncogenic role in the development and metastasis of HCC. (PMID:22327280)
• findings suggest that ARHGEF39 may contribute to cell proliferation and migration in gastric cancer via a possible mechanism involving Akt signaling. (PMID:28871449)
• ARHGEF39 promotes tumor growth and invasion by activating the Rac1-P38-ATF2 signaling pathway, as well as increasing the expression of Cyclin A2, Cyclin D1, and MMP2 in NSCLC cells. (PMID:29382922)
• FARP1, ARHGEF39, and TIAM2 are essential receptor tyrosine kinase effectors for Rac1-dependent cell motility in human lung adenocarcinoma. (PMID:34731623)
• Genome-wide admixture and association analysis identifies African ancestry-specific risk loci of eosinophilic esophagitis in African Americans. (PMID:36400179)
• ARHGEF39 targeted by E2F1 fosters hepatocellular carcinoma metastasis by mediating fatty acid metabolism. (PMID:39128592)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	arhgef39	ENSDARG00000013476
mus_musculus	Arhgef39	ENSMUSG00000051517
rattus_norvegicus	Arhgef39	ENSRNOG00000021433
caenorhabditis_elegans		WBGENE00001366
caenorhabditis_elegans		WBGENE00001490

Paralogs (10): FARP2 (ENSG00000006607), FGD1 (ENSG00000102302), FGD3 (ENSG00000127084), FGD4 (ENSG00000139132), FGD2 (ENSG00000146192), FARP1 (ENSG00000152767), FGD5 (ENSG00000154783), FRMD7 (ENSG00000165694), FGD6 (ENSG00000180263), ECT2L (ENSG00000203734)

Protein

Protein identifiers

Rho guanine nucleotide exchange factor 39 — Q8N4T4 (reviewed: Q8N4T4)

All UniProt accessions (1): Q8N4T4

UniProt curated annotations — full annotation on UniProt →

Function. Promotes cell proliferation.

Subcellular location. Cell membrane.

Tissue specificity. Strongly expressed in hepatocellular carcinoma (HCC) compared with their non-cancerous counterparts.

Isoforms (4)

UniProt ID	Names	Canonical?
Q8N4T4-1	1	yes
Q8N4T4-2	2
Q8N4T4-3	3
Q8N4T4-4	4

RefSeq proteins (1): NP_116207* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000219	DH_dom	Domain
IPR001849	PH_domain	Domain
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR035899	DBL_dom_sf	Homologous_superfamily
IPR042987	ARHGEF39	Family

Pfam: PF00169, PF00621

UniProt features (12 total): splice variant 6, domain 2, sequence variant 2, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N4T4-F1	92.99	0.84

Function

Pathways and Gene Ontology

Reactome pathways

12 pathways

ID	Pathway
R-HSA-193648	NRAGE signals death through JNK
R-HSA-416482	G alpha (12/13) signalling events
R-HSA-9013149	RAC1 GTPase cycle
R-HSA-162582	Signal Transduction
R-HSA-193704	p75 NTR receptor-mediated signalling
R-HSA-194315	Signaling by Rho GTPases
R-HSA-204998	Cell death signalling via NRAGE, NRIF and NADE
R-HSA-372790	Signaling by GPCR
R-HSA-388396	GPCR downstream signalling
R-HSA-73887	Death Receptor Signaling
R-HSA-9012999	RHO GTPase cycle
R-HSA-9716542	Signaling by Rho GTPases, Miro GTPases and RHOBTB3

MSigDB gene sets: 103 (showing top): WANG_CLIM2_TARGETS_UP, REACTOME_NRAGE_SIGNALS_DEATH_THROUGH_JNK, AREB6_01, FISCHER_G2_M_CELL_CYCLE, chr9p13, TGACATY_UNKNOWN, FISCHER_DREAM_TARGETS, YNGTTNNNATT_UNKNOWN, NUYTTEN_EZH2_TARGETS_DN, GOMF_GUANYL_NUCLEOTIDE_EXCHANGE_FACTOR_ACTIVITY, STAT5A_01, GOMF_NUCLEOSIDE_TRIPHOSPHATASE_REGULATOR_ACTIVITY, GOMF_ENZYME_REGULATOR_ACTIVITY, MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3, REACTOME_CELL_DEATH_SIGNALLING_VIA_NRAGE_NRIF_AND_NADE

GO Biological Process (1): positive regulation of cell migration (GO:0030335)

GO Molecular Function (2): guanyl-nucleotide exchange factor activity (GO:0005085), protein binding (GO:0005515)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-9 pathways:

Category	Pathways
Signal Transduction	3
Cell death signalling via NRAGE, NRIF and NADE	1
GPCR downstream signalling	1
RHO GTPase cycle	1
Death Receptor Signaling	1
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	1
p75 NTR receptor-mediated signalling	1
Signaling by GPCR	1
Signaling by Rho GTPases	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell migration	1
regulation of cell migration	1
positive regulation of cell motility	1
GTP binding	1
GDP binding	1
GTPase regulator activity	1
binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

856 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ARHGEF39	GALNT1	Q10472	550
ARHGEF39	ARHGEF9	O43307	491
ARHGEF39	CERS2	Q96G23	479
ARHGEF39	ARHGEF37	A1IGU5	468
ARHGEF39	RNLS	Q5VYX0	432
ARHGEF39	MCF2	P10911	432
ARHGEF39	CCDC107	Q8WV48	403
ARHGEF39	ARHGAP36	Q6ZRI8	397
ARHGEF39	HAUS6	Q7Z4H7	380
ARHGEF39	ABLIM2	Q6H8Q1	375
ARHGEF39	EPS8L1	Q8TE68	360
ARHGEF39	MPP3	Q13368	357
ARHGEF39	ABLIM3	O94929	352
ARHGEF39	CBFA2T3	O75081	351
ARHGEF39	EPS8L2	Q9H6S3	345

IntAct

30 interactions, top by confidence:

A	B	Type	Score
ARHGEF39	CALCOCO2	psi-mi:“MI:0915”(physical association)	0.670
TIFA	ARHGEF39	psi-mi:“MI:0915”(physical association)	0.670
CALCOCO2	ARHGEF39	psi-mi:“MI:0915”(physical association)	0.670
SLC31A1	C2orf72	psi-mi:“MI:0914”(association)	0.530
CACNG5	ZNF316	psi-mi:“MI:0914”(association)	0.530
IMPDH1	BCAT2	psi-mi:“MI:0914”(association)	0.530
ZNRD2	CCDC85C	psi-mi:“MI:0914”(association)	0.530
ARHGEF39	TYSND1	psi-mi:“MI:0915”(physical association)	0.500
DVL2	ARHGEF39	psi-mi:“MI:0915”(physical association)	0.370
RBPMS	ARHGEF39	psi-mi:“MI:0915”(physical association)	0.370
ARHGEF10	S100A8	psi-mi:“MI:0914”(association)	0.350
Tagap	PPIH	psi-mi:“MI:0914”(association)	0.350
PIPSL	C1orf226	psi-mi:“MI:0914”(association)	0.350
FTL	SH3PXD2B	psi-mi:“MI:0914”(association)	0.350
PTGES3	SBNO1	psi-mi:“MI:0914”(association)	0.350
ZNRD2	KRBA1	psi-mi:“MI:0914”(association)	0.350
CAMK2A	SMCHD1	psi-mi:“MI:0914”(association)	0.350
ARHGEF39	ACAA1	psi-mi:“MI:0914”(association)	0.350
IMPDH1	MGST3	psi-mi:“MI:0914”(association)	0.350
FTL		psi-mi:“MI:0914”(association)	0.350
KCTD12	CYTH3	psi-mi:“MI:0914”(association)	0.350

BioGRID (61): ARHGEF39 (Two-hybrid), TIFA (Two-hybrid), ARHGEF39 (Two-hybrid), ARHGEF39 (Two-hybrid), ARHGEF39 (Two-hybrid), ARHGEF39 (Affinity Capture-MS), ARHGEF39 (Affinity Capture-MS), ARHGEF39 (Affinity Capture-MS), ARHGEF39 (Affinity Capture-MS), ARHGEF39 (Affinity Capture-MS), BCR (Affinity Capture-Western), ARHGEF39 (Affinity Capture-MS), BCR (Affinity Capture-MS), CSDE1 (Affinity Capture-MS), CSTA (Affinity Capture-MS)

ESM2 similar proteins: A1IGU3, A1IGU4, A1IGU5, A6QP75, B2RUP2, D3ZI76, G1T469, P00530, P00542, P07332, P14238, P16879, Q0P5E3, Q14451, Q14DK4, Q1LZ97, Q3B7L1, Q3MIN7, Q3U5C8, Q3UYI5, Q53B87, Q53B88, Q58EX7, Q5VV41, Q5W0U4, Q60I26, Q60I27, Q66JY6, Q6DT37, Q6E804, Q6NUI2, Q6P5Z2, Q6PFY1, Q6PJ69, Q70J99, Q7Z6J4, Q80UW5, Q86WN1, Q8BTM9, Q8BY35

Diamond homologs: Q0P5E3, Q66JY6, Q69ZL1, Q8N4T4, A0A0D1E015, A0JMD2, A3LX75, A8QCE4, A8XJZ8, B0G126, B0WAQ0, B3MT31, B3P851, B4G2G5, B4IC49, B4JHI7, B4K982, B4M140, B4NFJ7, B4PRU6, D2H5P6, D3ZVP7, D4A8G9, E1BLZ4, F1P065, O13821, O14964, O59722, O76902, O88387, O95405, P0CS26, P0CS27, P34657, P40343, P52734, P98174, Q05B78, Q0P4S0, Q0V8S0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

116 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	90
Likely benign	8
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1210154	GRCh37/hg19 9p13.3-13.2(chr9:35059633-37660586)x1	Pathogenic

SpliceAI

2121 predictions. Top by Δscore:

Variant	Effect	Δscore
9:35660396:A:AG	acceptor_gain	1.0000
9:35660396:AACAG:A	acceptor_gain	1.0000
9:35660397:A:G	acceptor_gain	1.0000
9:35660398:CAGG:C	acceptor_loss	1.0000
9:35660399:A:AG	acceptor_gain	1.0000
9:35660399:A:C	acceptor_loss	1.0000
9:35660399:AG:A	acceptor_gain	1.0000
9:35660399:AGG:A	acceptor_gain	1.0000
9:35660399:AGGG:A	acceptor_gain	1.0000
9:35660400:G:GC	acceptor_loss	1.0000
9:35660400:G:GG	acceptor_gain	1.0000
9:35660400:GG:G	acceptor_gain	1.0000
9:35660400:GGG:G	acceptor_gain	1.0000
9:35660400:GGGG:G	acceptor_gain	1.0000
9:35660457:GTCAG:G	donor_gain	1.0000
9:35660461:GG:G	donor_loss	1.0000
9:35660462:G:A	donor_loss	1.0000
9:35660549:A:AG	acceptor_gain	1.0000
9:35660550:T:G	acceptor_gain	1.0000
9:35660553:CCA:C	acceptor_loss	1.0000
9:35660554:CA:C	acceptor_loss	1.0000
9:35660555:A:AC	acceptor_loss	1.0000
9:35660555:A:AG	acceptor_gain	1.0000
9:35660556:G:GC	acceptor_gain	1.0000
9:35660556:GA:G	acceptor_gain	1.0000
9:35660556:GAGC:G	acceptor_gain	1.0000
9:35660556:GAGCA:G	acceptor_gain	1.0000
9:35660643:GAGCG:G	donor_gain	1.0000
9:35660645:GCG:G	donor_gain	1.0000
9:35660646:CGG:C	donor_loss	1.0000

AlphaMissense

2141 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:35662207:A:G	W322R	0.982
9:35662207:A:T	W322R	0.982
9:35664091:A:C	F130L	0.977
9:35664091:A:T	F130L	0.977
9:35664093:A:G	F130L	0.977
9:35664758:G:C	S77R	0.973
9:35664758:G:T	S77R	0.973
9:35664760:T:G	S77R	0.973
9:35664845:A:C	F48L	0.969
9:35664845:A:T	F48L	0.969
9:35664847:A:G	F48L	0.969
9:35664017:C:G	R155P	0.963
9:35664101:A:G	F127S	0.963
9:35662259:G:C	F304L	0.961
9:35662259:G:T	F304L	0.961
9:35662261:A:G	F304L	0.961
9:35665081:A:G	L30P	0.961
9:35662205:C:A	W322C	0.960
9:35662205:C:G	W322C	0.960
9:35665069:T:A	E34V	0.958
9:35662239:A:T	L311H	0.957
9:35665113:C:A	W19C	0.956
9:35665113:C:G	W19C	0.956
9:35662651:A:T	L255H	0.955
9:35664788:A:C	F67L	0.955
9:35664788:A:T	F67L	0.955
9:35664790:A:G	F67L	0.955
9:35662651:A:G	L255P	0.954
9:35664781:A:G	W70R	0.954
9:35664781:A:T	W70R	0.954

dbSNP variants (sampled 300 via entrez): RS1000308916 (9:35661853 G>A,T), RS1000462230 (9:35662211 T>A), RS1000727643 (9:35661483 A>G,T), RS1000968517 (9:35666862 G>A,T), RS1001076608 (9:35661759 C>G), RS1001970786 (9:35665336 C>A,G,T), RS1001978453 (9:35659803 A>G), RS1002003254 (9:35665196 G>A), RS1002023911 (9:35667170 C>T), RS1002317041 (9:35659007 C>T), RS1002466740 (9:35659249 G>A,C), RS1002637570 (9:35664702 G>A,C), RS1003004942 (9:35663635 T>C), RS1003959520 (9:35667093 T>G), RS1004412779 (9:35666750 C>A)

Disease associations

OMIM: gene MIM:621172 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST90026413_8	Severe insulin-deficient type 2 diabetes	7.000000e-06

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

52 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects expression, decreases expression, affects cotreatment, increases abundance, increases expression	4
Air Pollutants	affects expression, increases abundance, decreases expression	2
Tobacco Smoke Pollution	decreases expression	2
aristolochic acid I	decreases expression	1
methylmercuric chloride	decreases expression	1
bisphenol A	affects cotreatment, decreases methylation	1
trichostatin A	affects expression	1
beta-lapachone	decreases expression	1
sulforaphane	increases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
rutecarpine	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
pentabromodiphenyl ether	decreases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
NSC668394	decreases expression	1
Irinotecan	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Leflunomide	decreases expression	1
Acetaminophen	decreases expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Benzo(a)pyrene	decreases expression	1
Calcitriol	decreases expression, affects cotreatment	1
Coumestrol	increases expression	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Drugs, Chinese Herbal	decreases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_XL47	HAP1 ARHGEF39 (-) 1	Cancer cell line	Male
CVCL_XL48	HAP1 ARHGEF39 (-) 2	Cancer cell line	Male
CVCL_XL49	HAP1 ARHGEF39 (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice